Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1985 Jun;21(6):997–999. doi: 10.1128/jcm.21.6.997-999.1985

Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine.

M L Clements, E L Tierney, B R Murphy
PMCID: PMC271838  PMID: 4008629

Abstract

The infectivity and immunogenicity of live attenuated A/Washington/897/80 cold-adapted reassortant virus vaccine was evaluated in seronegative (hemagglutination inhibition titer, less than or equal to 1:4) and seropositive (hemagglutination inhibition titer, greater than 1:4) adult volunteers. The vaccine was efficient in infecting seronegative volunteers (94%). Moreover, 51% of seropositive vaccinees were infected by the virus. After live virus vaccination, greater than 83% of both seronegative and seropositive vaccinees achieved a level of nasal wash antibody previously associated with resistance to infection with influenza A virus. These findings indicate that both seronegative and seropositive vaccinees can benefit from live virus vaccination.

Full text

PDF
997

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clements M. L., Betts R. F., Maassab H. F., Murphy B. R. Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers. J Infect Dis. 1984 May;149(5):814–815. doi: 10.1093/infdis/149.5.814. [DOI] [PubMed] [Google Scholar]
  2. Clements M. L., Betts R. F., Murphy B. R. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984 Mar 31;1(8379):705–708. doi: 10.1016/s0140-6736(84)92222-0. [DOI] [PubMed] [Google Scholar]
  3. Clements M. L., O'Donnell S., Levine M. M., Chanock R. M., Murphy B. R. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun. 1983 Jun;40(3):1044–1051. doi: 10.1128/iai.40.3.1044-1051.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hobson D., Curry R. L., Beare A. S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972 Dec;70(4):767–777. doi: 10.1017/s0022172400022610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. La Montagne J. R., Noble G. R., Quinnan G. V., Curlin G. T., Blackwelder W. C., Smith J. I., Ennis F. A., Bozeman F. M. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis. 1983 Jul-Aug;5(4):723–736. doi: 10.1093/clinids/5.4.723. [DOI] [PubMed] [Google Scholar]
  6. Liew F. Y., Russell S. M., Appleyard G., Brand C. M., Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol. 1984 Apr;14(4):350–356. doi: 10.1002/eji.1830140414. [DOI] [PubMed] [Google Scholar]
  7. McDonald J. C., Zuckerman A. J., Beare A. S., Tyrrell D. A. Trials of Live Influenza Vaccine in the Royal Air Force. Br Med J. 1962 Apr 14;1(5284):1036–1042. doi: 10.1136/bmj.1.5284.1036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Murphy B. R., Clements M. L., Madore H. P., Steinberg J., O'Donnell S., Betts R., Demico D., Reichman R. C., Dolin R., Maassab H. F. Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis. 1984 May;149(5):816–816. doi: 10.1093/infdis/149.5.816. [DOI] [PubMed] [Google Scholar]
  9. Murphy B. R., Phelan M. A., Nelson D. L., Yarchoan R., Tierney E. L., Alling D. W., Chanock R. M. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol. 1981 Mar;13(3):554–560. doi: 10.1128/jcm.13.3.554-560.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rubin R. J., Noble G. R., Corey L., Brown W. J., Jr, Brandling-Bennett D., Kaye H. S., Coleman M. T., Gregg M. B., Dowdle W. R. Live, attenuated influenza A/England/42/72 (H3N2) virus vaccine: a field trial. J Infect Dis. 1976 Jun;133(6):613–620. doi: 10.1093/infdis/133.6.613. [DOI] [PubMed] [Google Scholar]
  11. Wright P. F., Okabe N., McKee K. T., Jr, Maassab H. F., Karzon D. T. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis. 1982 Jul;146(1):71–79. doi: 10.1093/infdis/146.1.71. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES